Antibodies targeting cytotoxic T-lymphocyte protein 4 (CLTA-4) have faced challenges due to frequent adverse events and limited efficacy, thus pushing the search for next-generation anti-CTLA-4 antibodies that balance T regulatory cell (Treg) depletion with CD8 T-cell activation for cancer immunotherapy.